NCT01462292View on ClinicalTrials.gov

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 26, 2011

Primary Completion Date

May 21, 2013

Study Completion Date

November 4, 2013

Conditions
Muscular Dystrophies
Interventions
DRUG

GSK2402968 3mg/kg/week

Comparison of 2 doses of GSK2402968

DRUG

GSK2402968 6 mg/kg/week

Comparison of 2 doses of GSK2402968

DRUG

Placebo to match GSK2402968 3 mg/kg/week

Matched placebo

DRUG

Placebo to match GSK2402968 6 mg/kg/week

Matched Placebo

Trial Locations (14)

10032

GSK Investigational Site, New York

21205

GSK Investigational Site, Baltimore

27710

GSK Investigational Site, Durham

32561

GSK Investigational Site, Gulf Breeze

43205

GSK Investigational Site, Columbus

45229

GSK Investigational Site, Cincinnati

52242

GSK Investigational Site, Iowa City

55455

GSK Investigational Site, Minneapolis

63110

GSK Investigational Site, St Louis

66160

GSK Investigational Site, Kansas City

75207

GSK Investigational Site, Dallas

94305

GSK Investigational Site, Stanford

95817

GSK Investigational Site, Sacramento

97239

GSK Investigational Site, Portland

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01462292 - A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter